Ser245

Site Information
FSNPDNGsPAMtHRN SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 2047937

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ) , mutation of modification site ( 1 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 2 , 6 ) , 'brain, cerebellum' ( 26 ) , 'brain, cerebral cortex' ( 26 ) , 'brain, hippocampus, dentate gyrus' ( 26 ) , 'brain, midbrain' ( 26 ) , 'fat, brown' ( 10 ) , astrocyte ( 1 ) , brain ( 8 , 9 , 10 , 11 , 14 ) , fibroblast-lung ( 23 ) , heart ( 10 ) , HeLa (cervical) ( 1 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 3 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 3 ) , HL-1 (myocyte) ( 3 ) , kidney ( 10 ) , liver ( 5 , 7 , 10 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 24 , 25 ) , liver [leptin (mouse), homozygous knockout] ( 7 ) , lung ( 10 )

In vivo Characterization

Methods used to characterize site in vivo:

mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ) , mutation of modification site ( 1 )

Relevant cell line - cell type - tissue:

'3T3-L1, differentiated' (adipocyte) ( 2 , 6 ) , 'brain, cerebellum' ( 26 ) , 'brain, cerebral cortex' ( 26 ) , 'brain, hippocampus, dentate gyrus' ( 26 ) , 'brain, midbrain' ( 26 ) , 'fat, brown' ( 10 ) , astrocyte ( 1 ) , brain ( 8 , 9 , 10 , 11 , 14 ) , fibroblast-lung ( 23 ) , heart ( 10 ) , HeLa (cervical) ( 1 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 3 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 3 ) , HL-1 (myocyte) ( 3 ) , kidney ( 10 ) , liver ( 5 , 7 , 10 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 24 , 25 ) , liver [leptin (mouse), homozygous knockout] ( 7 ) , lung ( 10 )

Upstream Regulation
Putative in vivo kinases:	mTOR (human) ( 1 )
Treatments:	3BDO ( 1 ) , insulin ( 6 ) , rapamycin ( 1 )

Downstream Regulation
Effects of modification on SLC4A4:	activity, inhibited ( 1 )

References
1	Giannaki M, Ludwig C, Heermann S, Roussa E (2021) Regulation of electrogenic Na /HCO cotransporter 1 (NBCe1) function and its dependence on m-TOR mediated phosphorylation of Ser. J Cell Physiol 34642952 Curated Info
2	Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6 26060331 Curated Info
3	Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45 25162660 Curated Info
4	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
5	Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86 23567750 Curated Info
6	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
7	Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83 23140645 Curated Info
8	Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29 22645316 Curated Info
9	Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9 22807455 Curated Info
10	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
11	Possemato A (2010) CST Curation Set: 9876; Year: 2010; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
12	Possemato A (2010) CST Curation Set: 9881; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
13	Possemato A (2010) CST Curation Set: 9880; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
14	Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9 20415495 Curated Info
15	Possemato A (2010) CST Curation Set: 9736; Year: 2010; Biosample/Treatment: tissue, liver/AICAR; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
16	Possemato A (2010) CST Curation Set: 9733; Year: 2010; Biosample/Treatment: tissue, liver/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
17	Possemato A (2010) CST Curation Set: 9747; Year: 2010; Biosample/Treatment: tissue, liver/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
18	Possemato A (2010) CST Curation Set: 9748; Year: 2010; Biosample/Treatment: tissue, liver/AICAR; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
19	Possemato A (2010) CST Curation Set: 9745; Year: 2010; Biosample/Treatment: tissue, liver/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
20	Possemato A (2010) CST Curation Set: 9734; Year: 2010; Biosample/Treatment: tissue, liver/AICAR; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
21	Possemato A (2010) CST Curation Set: 9735; Year: 2010; Biosample/Treatment: tissue, liver/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
22	Possemato A (2010) CST Curation Set: 9746; Year: 2010; Biosample/Treatment: tissue, liver/AICAR; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
23	Guo A (2010) CST Curation Set: 9029; Year: 2010; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
24	Guo A (2009) CST Curation Set: 7821; Year: 2009; Biosample/Treatment: tissue, liver/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
25	Guo A (2009) CST Curation Set: 7819; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
26	Trinidad JC, et al. (2008) Quantitative analysis of synaptic phosphorylation and protein expression. Mol Cell Proteomics 7, 684-96 18056256 Curated Info